

## Pharmaceutical Policies Updates Effective January 1, 2021

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at [mvphealthcare.com](http://mvphealthcare.com) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy.
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs.
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change.
- **Archived** – Denotes a policy that is no longer active.

The following policy is effective January 1, 2021 and will be available to view on December 1, 2020. Hard copies of the policy are available upon request.

Pharmaceutical Policy Name	Status
Multiple Sclerosis Agents	Updated
Xyrem (sodium oxybate)	Updated
Movement Disorders	Reviewed
Benlysta (belimumab)	Updated
Respiratory Syncytial Virus/Synagis	Reviewed
Gabapentin ER	Updated
Nuedexta	Reviewed
Immunoglobulin Therapy	Updated
Select Hypnotics	Updated
Formulary Exception of Non-Covered Drugs (External)	Reviewed
Spinal Muscular Atrophy (SMA) – (effective 11/2/2020)	Updated
Zulresso	Updated
Radicava	Reviewed

To view all communications, visit [mvphealthcare.com/FastFax](http://mvphealthcare.com/FastFax)

To receive future FastFax messages by email, send a request to [MVPFastFax@mvphealthcare.com](mailto:MVPFastFax@mvphealthcare.com).

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

